Daniela Buglio

1.8k total citations
36 papers, 1.2k citations indexed

About

Daniela Buglio is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Daniela Buglio has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 13 papers in Pathology and Forensic Medicine and 13 papers in Oncology. Recurrent topics in Daniela Buglio's work include Histone Deacetylase Inhibitors Research (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Protein Degradation and Inhibitors (9 papers). Daniela Buglio is often cited by papers focused on Histone Deacetylase Inhibitors Research (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Protein Degradation and Inhibitors (9 papers). Daniela Buglio collaborates with scholars based in United States, Italy and France. Daniela Buglio's co-authors include Anas Younes, Noor M. Khaskhely, Georgios Georgakis, Sattva S. Neelapu, Amanda Copeland, Yuan Ji, L. Jeffrey Medeiros, Jorge Romaguera, Enrico Derenzini and Kazuhiko Arima and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Daniela Buglio

36 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Buglio United States 16 745 454 447 205 188 36 1.2k
Archito T. Tamayo United States 16 631 0.8× 412 0.9× 393 0.9× 246 1.2× 413 2.2× 34 1.2k
Jennifer E. Amengual United States 15 574 0.8× 408 0.9× 450 1.0× 137 0.7× 214 1.1× 87 1.1k
Laurence Cooke United States 19 532 0.7× 505 1.1× 213 0.5× 149 0.7× 215 1.1× 39 1.1k
Lan V. Pham United States 23 822 1.1× 556 1.2× 580 1.3× 389 1.9× 583 3.1× 57 1.7k
Kedar Inamdar United States 15 393 0.5× 253 0.6× 276 0.6× 156 0.8× 141 0.8× 39 772
Cory Mavis United States 16 441 0.6× 285 0.6× 245 0.5× 159 0.8× 120 0.6× 74 754
Francesco Paolo Tambaro United States 16 789 1.1× 309 0.7× 211 0.5× 262 1.3× 187 1.0× 40 1.3k
Debora Rasio Italy 16 876 1.2× 467 1.0× 259 0.6× 226 1.1× 79 0.4× 25 1.4k
Seong Lin Khaw Australia 17 958 1.3× 440 1.0× 252 0.6× 440 2.1× 245 1.3× 37 1.6k
Michael Grau Germany 17 597 0.8× 417 0.9× 394 0.9× 274 1.3× 496 2.6× 30 1.3k

Countries citing papers authored by Daniela Buglio

Since Specialization
Citations

This map shows the geographic impact of Daniela Buglio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Buglio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Buglio more than expected).

Fields of papers citing papers by Daniela Buglio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Buglio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Buglio. The network helps show where Daniela Buglio may publish in the future.

Co-authorship network of co-authors of Daniela Buglio

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Buglio. A scholar is included among the top collaborators of Daniela Buglio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Buglio. Daniela Buglio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eeckhout, Peter, et al.. (2022). CROSSED EXPERIMENTATIONS OF LOW-ALTITUDE SURVEYS FOR THE DETECTION OF BURIED STRUCTURES. SHILAP Revista de lepidopterología. XLVI-2/W1-2022. 505–512. 3 indexed citations
2.
Batlevi, Connie Lee, Yvette L. Kasamon, Peter Lee, et al.. (2016). ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica. 101(8). 968–975. 40 indexed citations
3.
Frolova, Olga, Ismael Samudio, Juliana M. Benito, et al.. (2012). Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biology & Therapy. 13(10). 858–870. 96 indexed citations
4.
Lemoine, Manuela, Enrico Derenzini, Daniela Buglio, et al.. (2012). The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 119(17). 4017–4025. 68 indexed citations
5.
Khaskhely, Noor M., Daniela Buglio, Enrico Derenzini, et al.. (2011). The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental Hematology. 39(10). 1007–1017.e1. 39 indexed citations
6.
Younes, Anas, Yasuhiro Oki, R. Gregory Bociek, et al.. (2011). Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. The Lancet Oncology. 12(13). 1222–1228. 156 indexed citations
7.
Derenzini, Enrico, et al.. (2011). Novel Therapy of Relapsed and Refractory Classical Hodgkin’s Lymphoma. European Oncology & Haematology. 7(3). 203–203. 1 indexed citations
8.
Buglio, Daniela, Manuela Lemoine, Sattva S. Neelapu, et al.. (2011). NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival. Blood. 118(21). 4965–4965. 1 indexed citations
9.
Buglio, Daniela, Manuela Lemoine, Sattva S. Neelapu, et al.. (2011). The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,. Blood. 118(21). 3729–3729. 4 indexed citations
10.
Buglio, Daniela, Noor M. Khaskhely, Kui Shin Voo, et al.. (2011). HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood. 117(10). 2910–2917. 91 indexed citations
11.
Derenzini, Enrico, Manuela Lemoine, Daniela Buglio, et al.. (2011). The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer Journal. 1(12). e46–e46. 52 indexed citations
12.
Copeland, Amanda, Daniela Buglio, & Anas Younes. (2010). Histone deacetylase inhibitors in lymphoma. Current Opinion in Oncology. 22(5). 431–436. 29 indexed citations
13.
Buglio, Daniela & Anas Younes. (2010). Histone deacetylase inhibitors in Hodgkin lymphoma. Investigational New Drugs. 28(S1). 21–27. 22 indexed citations
14.
Buglio, Daniela, Francisco Vega, Sattva S. Neelapu, et al.. (2010). Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma. Blood. 116(21). 2852–2852. 2 indexed citations
15.
Buglio, Daniela, Vidya Mamidipudi, Noor M. Khaskhely, et al.. (2010). The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism. British Journal of Haematology. 151(4). 387–396. 44 indexed citations
16.
Younes, Anas, F Hernández, R. Gregory Bociek, et al.. (2010). ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results. Blood. 116(21). 3959–3959. 7 indexed citations
17.
Gloghini, Annunziata, Daniela Buglio, Noor M. Khaskhely, et al.. (2009). Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. British Journal of Haematology. 147(4). 515–525. 78 indexed citations
18.
Buglio, Daniela, Georgios Georgakis, Shino Hanabuchi, et al.. (2008). Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 112(4). 1424–1433. 133 indexed citations
19.
Yazbeck, Victor, Daniela Buglio, Georgios Georgakis, et al.. (2008). Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Experimental Hematology. 36(4). 443–450. 118 indexed citations
20.
Buglio, Daniela, Georgios Georgakis, & Anas Younes. (2007). Novel small-molecule therapy of Hodgkin lymphoma. Expert Review of Anticancer Therapy. 7(5). 735–740. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Archito T. Tamayo Breakdown of academic impact, for papers by Jennifer E. Amengual Breakdown of academic impact, for papers by Laurence Cooke Breakdown of academic impact, for papers by Lan V. Pham Breakdown of academic impact, for papers by Kedar Inamdar Breakdown of academic impact, for papers by Cory Mavis Breakdown of academic impact, for papers by Francesco Paolo Tambaro Breakdown of academic impact, for papers by Debora Rasio Breakdown of academic impact, for papers by Seong Lin Khaw Breakdown of academic impact, for papers by Michael Grau
Rankless by CCL
2026